EXPRESSION OF ONCOGENES IN LYMPHOPROLIFERATIVE DISORDERS

我们继续对bcl2在卵泡中的表达进行研究。 淋巴瘤。我们开发了一种分离RNA的程序，随后 Bcl2/重链的逆转录和聚合酶链式反应扩增 序列。使用这种方法，我们能够测量出 Bcl2在小标本中的表达。我们比较了我们的技术 在携带t(14；18)的细胞系中 Northern印迹分析，证明了我们方法的有效性。 利用这一程序，我们测量了bcl2的表达水平。 在一系列活组织检查样本中。我们目前正在将我们的 结果与临床结果相吻合。研究表明，bcl-2可能会导致 对细胞的生长有利，但其他癌基因的参与， 尤其是myc，是充分发挥恶性潜能所必需的。我们有 开发了一种类似的技术，利用pcr来测量myc转录本。 并对该方法的有效性进行了评估。 PHA刺激外周血T细胞，并将我们的PCR结果与 Northern印迹数据。我们正在研究myc在卵巢癌组织中的表达。 滤泡性淋巴瘤研究bcl2“的表达。此外，我们是 恶性淋巴瘤中myc基因表达的研究 更具侵袭性的表型以确定myc表达是否与 具有这种表型。这将提供有关 多种癌基因在卵泡发育中的相互关系 淋巴瘤。

We have continued our studies of the expression of bcl-2 in follicular lymphoma. We developed a procedure for isolation of RNA followed by reverse transcription and PCR amplification of bcl-2/heavy chain sequences. Using this method, we are able to measure the level of expression of bcl-2 in small specimens. We have compared our technique in cell lines carrying the t(14;18) with the standard procedure of Northern blot analysis and have documented the validity of our method. Using this procedure, we have measured the levels of expression of bcl-2 in a series of biopsy specimens. We are currently correlating our results with clinical outcome. Studies indicate that bcl-2 may incur a growth advantage to cells but that involvement of other oncogenes, especially myc, is necessary to attain full malignant potential. We have developed a similar technique utilizing PCR to measure myc transcripts and have evaluated the validity of this method using non-stimulated and PHA stimulated peripheral blood T cells and comparing our PCR results to Northern blot data. We are studying the expression of myc in the follicular lymphomas studied for bcl-2 "expression. In addition, we are studying the expression of myc in lymphomas that have progressed to a more aggressive phenotype to determine if myc expression is associated with this phenotype. This will provide important information as to the interrelationship of various oncogenes in the development of follicular lymphoma.